Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation/Expansion Study of SLV-154 in Subjects With Advanced Cancers

NCT06771219 is registered in ClinicalTrials.gov with Solve Therapeutics as lead sponsor.

NCT NCT06771219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06771219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation/Expansion Study of SLV-154 in Subjects With Advanced Cancers
Lead sponsor
Solve Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
May 14, 2025
Completion date
November 30, 2027
Enrollment
250 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, metastatic cancer